EP1928874A1 — Heterobicyclic compounds as glucokinase activators
Assigned to AstraZeneca AB · Expires 2008-06-11 · 18y expired
What this patent protects
Compounds of Formula (I) wherein R1 to R11, A and X1 to X3 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are al…
USPTO Abstract
Compounds of Formula (I) wherein R1 to R11, A and X1 to X3 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.